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Abstract
Background: There has been limited data addressing outcomes of extensive septal myectomy in Chinese patients
with hypertrophic obstructive cardiomyopathy (HOCM). In this study, the objective was to evaluate the clinical and
echocardiographic outcomes of extensive septal myectomy in a relative large number of Chinese HOCM patients
over long-term follow-up.
Methods: We retrospectively studied 139 consecutive HOCM patients (age 43 ± 15 years, 37 % male) who
underwent extensive left ventricular septal myectomy. During the perioperative period, all patients were examined
by echocardiography. All-cause death and cardiac death were considered as primary endpoints during follow-up.
Perioperative data was obtained by retrospective review of institutional surgical databases. Follow-up data of
echocardiography and clinical status was recorded through outpatient interview.
Results: Perioperative events consisted of arrhythmia, retraction injury to aortic valve leaflets, pleural effusion, and
hemodialysis and the use of intra-aortic balloon pump. There was no in-hospital mortality. The follow-up period
averaged 5.6 ± 0.9 years and overall survivals were 100.0, 99.3, 99.3, 98.5 and 97.8 % at 1, 2, 3, 4 and 5 years, respectively.
Left ventricular outflow tract (LVOT) gradient decreased form preoperative 84 ± 17 mmHg to 12 ± 3 mmHg at 2.5 years
after surgery and it further reduced to 6 ± 3 mmHg at 5 years after surgery (P < 0.05). Compared with the preoperative
levels, interventricualr septal thickness decreased by 32 % while diastole left ventricular inner diameter approximately
increased by 10 % and ejection fraction (EF) was significantly elevated during follow-up (P < 0.05). By echocardiography
detection, mitral regurgitation was ameliorated for HOCM patients after surgery. There was significant improvement in
New York Heart Association (NYHA) class. The proportion of NYHA III and IV decreased from preoperative 58 to 19 % at
2.5 years after surgery and it reduced to 11 % at 5 years after operation.
Conclusion: Extensive septal myectomy offers minimal operative risk and provides long-term relief for LVOT
obstruction in Chinese HOCM patients.
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Background
Hypertrophic cardiomyopathy (HCM) is estimated to
affect 0.2 % of the population [1, 2]. As the most com-
mon inherited cardiac disease, HCM is characterized by
asymmetrical septal hypertrophy [3, 4]. The phenotypes
are ranging from minor to severe life-threatening status
[5]. Left ventricular outflow tract (LVOT) obstruction is
responsible for disabling symptoms in a large proportion
of patients and confers a worse prognosis. HCM is the
most common cause of sudden cardiac death (SCD) in
people aged less than 35 years. In fact, it is more com-
mon for HCM patients to develop to severe progressive
heart failure than SCD.
Septal myectomy is considered as the gold standard
for septal reduction therapy in patients with dynamic
LVOT obstruction [6]. The long-term mortality for
hypertrophic obstructive cardiomyopathy (HOCM) pa-
tients with septal myectomy reduction therapy decreases
to 1.4–1.8 % [7, 8]. Septal myectomy has contributed to
the overall reduction in mortality and provided survival
equivalent to that of the general population [9]. The op-
erative technique of HOCM has undergone evolution
from classic Morrow surgery to extensive resection. Ex-
tensive septal myectomy surgery has evolved into a com-
prehensive repair technique for LVOT obstruction and
abnormality of the mitral apparatus [10]. Extension of
the myectomy area leads to improved surgical effect.
Currently, there are limited data addressing long-term
outcome of extensive septal myectomy in Chinese pa-
tients with HOCM. In the present study, we sought to
report the early and late clinical and echocardiographic
outcomes of Chinese HOCM patients who underwent
extensive septal myectomy surgery.
Methods
HOCM patients
This study was carried out in 139 consecutive HOCM
patients treated with extensive surgical myectomy in
Cangzhou Central hospital and Shandong Chinese Med-
ical Hospital from Jan 1, 2008 to May 31, 2011. Patients
were eligible for inclusion in surgical intervention if they
met the following two criteria [11]: 1) LVOT pressure
gradient ≥50 mmHg at rest or with physiological provo-
cation by transthoracic echocardiography; 2) presence of
severe symptoms despite prior appropriate medical ther-
apy with beta-receptor blocker and calcium channel
blocker. All patients were evaluated by consultant cardi-
ologists. Although they were given medical therapy, they
still had severe symptoms attributable to LVOT obstruc-
tion. The review of hospital records and analyses of pre-
operative data, operative reports, postoperative and
follow-up echocardiography were carried out. In this
study, perioperative period was defined as time period
from surgical preparation to 30 days after extensive
septal myectomy. The study had full approval from the
Ethics Boards of Cangzhou Central hospital and Shandong
Chinese Medical Hospital.
Surgical procedure
Operations were carried out under mild hypothermic car-
diopulmonary bypass with total anesthesia as previously
described [12, 13]. The heart and ascending aorta were ex-
posed by a longitudinal median incision in sternum. Can-
nulas were inserted into superior vena cava, inferior vena
cava and ascending aorta to establish cardiopulmonary by-
pass. Through a transverse aortotomy, the aortic valve
was exposed and cardiac asystole was induced by cold
blood antegrade cardioplegia. Hypertrophic septum and
mitral valve were exposed sufficiently by pulling right cor-
onary aortic valve. A Ross retractor was used to display
the muscular septum. The superior borderline of septal re-
section located at 3 mm below right coronary sinus valve.
Resection started from middle of right aortic sinus and
moved 10–12 mm horizontally toward commissure of left
sinus valve and right sinus valve. Longitudinal resection
usually reached the root of mitral papillary muscle, length
of which ranged from 45 to 50 mm. In order to reduce
LVOT gradient, the thicknesses of the left ventricular wall
and interventricular septum need to be nearly normal by
visual inspection.
The following extended procedures were performed as
previously described [14, 15]: 1) The resection was con-
tinued toward the mitral valve annulus and apically to
the bases of the papillary muscles. 2) All areas of papil-
lary muscle fusion to the septum or ventricular free wall
are divided, and anomalous chordal structures and fi-
brous attachments of the mitral leaflets to the ventricu-
lar septum are excised. 3) Plication of the anterior mitral
leaflet (AML) was performed if there were indications by
selection criteria including floppy and lax anterior leaf-
let, AML ≥ 3.0 cm, mitral regurgitation ≥ 2+, systolic an-
terior motion (SAM), and/or absence of rheumatic or
other intrinsic mitral valve disease. Intraoperative trans-
esophageal echocardiography (TEE) was used routinely.
TEE assessment was performed after weaning from car-
diopulmonary bypass to evaluate adequacy of LVOT and
mitral valve function.
Postoperative monitor was carried out to maintain
proper cardiac preload and appropriate colloid infusion.
Beta-receptor blocker or calcium-channel blocker was
applied routinely. Low-dose vasoactive drugs were used
when hemodynamic circulation fluctuated.
Echocardiography
During hospital stay, preoperative transthoracic echocar-
diography was performed for HOCM patients and intra-
operative TEE was applied routinely. The adequacy of the
resection and the LVOT gradient were assessed immediately
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by transthoracic echocardiography after surgery and trans-
thoracic echocardiography was repeated before or on the
day of hospital discharge. During outpatient follow-up
period, patients had transthoracic echocardiography detec-
tion at every visit. A careful analysis of septal hypertrophy,
abnormalities of the mitral valve, and subvalvular apparatus
was performed. LVOT gradient was detected at rest and
with provocation by transthoracic echocardiography. Spe-
cific details of mitral valve length, SAM, and mitral regurgi-
tation were evaluated. Images were captured on cine loops
at the time of the detection. M-mode from long axis view
was used to measure interventricualr septal (IVS) thickness
and diastole left ventricular inner diameter (LVIDd). M-
mode from short axis view was used to measure thickness
of left ventricular wall. Ejection fraction (EF) was automatic-
ally calculated by the measurement package.
Follow-up
The follow-up period averaged 5.6 ± 0.9 years for HOCM
patients. Follow-up data were derived from medical charts
and LVOT gradient information was obtained from the
record of transthoracic echocardiography detection at
every outpatient visit. Our primary endpoints included all-
cause death and cardiac death during follow-up. Cardiac
death was defined as a death resulting from heart failure
or SCD. SCD was defined as an abrupt loss of conscious-
ness within 1 h after the onset of acute symptoms, and the
cause of death could not be attributed in the postmortem
examination. All patients were assigned New York Heart
Association (NYHA) classification based on symptoms.
Statistical analysis
Continuous variables were expressed as mean ± SD
otherwise described as proportion. χ2 test was used to
compare categorical variables. For continuous variables,
one-way ANOVA was used to analyze the data among
three groups and then paired t test was performed for
the comparison between two groups. The Kaplan-Meier
method was used to draw survival curve and calculate
survival rate and cumulate hazard. Difference was con-
sidered statistically significant when P < 0.05. All statis-




Clinical characteristics of 139 HOCM patients with mean
age 43 ± 15 years were shown in Table 1. Females were
more than males. Body mass index was 28 ± 8 kg/m2 and
heart rate was 74 ± 5 beat/min. All patients received med-
ical therapy with beta-receptor blocker or calcium channel
blocker. Most patients had severe preoperative symptoms
including dyspnea, chest pain, and syncope. Family history
of HCM was presented in 54.7 % of subjects. Hypertension,
diabetes and dyslipidemia were prevalent in the HOCM
patients. The majority of HOCM patients belonged to
NYHA III.
Perioperative events and complications
Adjunctive surgical procedures were summarized in Table 2.
Overall, cardiopulmonary bypass time was 133 ± 40 min
and aorta cross-clamp time was 85 ± 26 min. Postoperative
intensive care unit (ICU) stay time was 3 ± 3 days. Mechan-
ical ventilation time was 24 ± 15 h. Postoperative hospital
stay time was 10 ± 5 days.
The 139 patients had no early death within 30 days after
extensive septal myectomy. Perioperative arrhythmia was
shown in Table 3. In this study, perioperative arrhythmia
events included atrial fibrillation, atrial premature beat, ven-
tricular premature beat, atrioventricular block, left bundle
branch block, left anterior fascicular block and right bundle
Table 1 Clinical characteristics
Variables Values
n 139
Age (y) 43 ± 15
Male 52 (37.4 %)
Body mass index (kg/m2) 28 ± 8
Heart rate (beat/min) 74 ± 5
SBP (mmHg) 113 ± 12
DBP (mmHg) 73 ± 9
Symptoms
Dyspnea 133 (95.7 %)
Chest pain 73 (52.5 %)
Syncope 33 (23.7 %)
Hypertension 44 (31.7 %)
Diabetes 25 (18 %)
Dyslipidemia 101 (72.7 %)
Family history of HCM 76 (54.7 %)
Medical therapy
Beta-receptor blocker 16 (11.5 %)
Calcium channel blocker 43 (30.9 %)
SBP systolic blood pressure, DBP diastolic blood pressure
Table 2 Adjunctive procedures
Procedure n (%) Age (y)
CABG 11 (7.9 %) 56 ± 16
LV aneurysmectomy 2 (1.4 %) 40 ± 17
MV replaement 7 (5 %) 46 ± 14
MV repair 17 (12.2 %) 44 ± 9
AV repair 4 (2.9 %) 61 ± 19
TV repair 6 (4.3 %) 42 ± 16
CABG coronary artery bypass graft, LV left ventricle, MV mitral valve, AV aortic
valve, TV tricuspid valve
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branch block. There was a preoperative history of atrial fib-
rillation in 13 patients while postoperative new atrial fibrilla-
tion occurred in 11 patients. In total, there were 16 patients
suffering from atrial ventricular block after surgery. Perman-
ent pacemaker was implanted for 8 (5.8 %) patients with
complete atrioventricular block. None of the patients needed
implantable cardioverter defibrillator (ICD) during early
postoperative period. In addition, retraction injury to aortic
valve leaflets occurred in 5 patients. One patient needed the
mechanical support of intra-aortic balloon pump (IABP) im-
mediately following surgery. Postoperative pleural effusion
happened in 25 patients. Hemodialysis was used for 2 pa-
tients. Two patients were subjected to second intubation
and 1 patient underwent tracheotomy. Second transfer to
ICU was required for 1 patient on postoperative 7th day.
Clinical and echocardiographic follow-up
Clinical follow-up was 5.6 ± 0.9 years (minimum 1.2 years
and maximum 7.9 years). Four patients were lost to late
follow-up. Overall survival was 100.0, 99.3, 99.3, 98.5
and 97.8 % at 1, 2, 3, 4 and 5 years, respectively (Fig. 1).
One patient died of cardiac origin and 2 patients had
undiagnosed sudden death.
Follow-up outcomes indicated the symptoms were signifi-
cantly attenuated and physical abilities were increased. Im-
provement in NYHA class was shown in Fig. 2. The
proportion of NYHA III and IV decreased from preopera-
tive 58 to 19 % at 2.5 years after surgery while it reduced to
11 % at 5 years after operation. LVOT gradient decreased
form preoperative 84 ± 17 mmHg to 12 ± 3 mmHg at
2.5 years after surgery and it further reduced to 6 ± 3 mmHg
at 5 years after surgery (P < 0.05, Fig. 3). Compared with the
level of preoperative IVS thickness, IVS thickness decreased
by 32 % at postoperative 2.5 years and maintained the same
low level at postoperative 5 years (P < 0.05, Fig. 3). LVIDdap-
proximately increased by 10 % at postoperative
2.5 years and 5 years, compared with the level before surgery
(P < 0.05, Fig. 3). Similarly, EF was significantly elevated at
2.5 years and 5 years after extensive septal myectomy
(P < 0.05, Fig. 3). By transthoracic echocardiography detec-
tion, mitral regurgitation was ameliorated for patients after
surgery. There were 52 % of patients showing moderate mi-
tral regurgitation and 8 % of patients had severe mitral
regurgitation before surgery. Preoperative mild mitral regur-
gitation existed in 40 % of patients. With extensive septal
myectomy, both severe mitral regurgitation and moderate
mitral regurgitation disappeared. The proportion of postop-
erative mild mitral regurgitation increased to 89 and 11 % of
patients did not have mitral regurgitation any more.
Discussion
The present study included a relative large of Chinese
HOCM patients who were treated by extensive septal
myectomy in two hospitals. Our results showed that
extensive septal myectomy significantly reduced LVOT
obstruction, mitral regurgitation and HOCM-related
symptoms. Cardiac function was obviously increased by
surgical treatment. Extensive septal myectomy and ad-
junctive procedures could be an efficacious and low-risk
therapy in Chinese HOCM patients. It gives predictable,
immediate, and durable remodeling of the LVOT which
translates into long-term control of symptoms.
Extensive septal myectomy surgery in HOCM
HOCM, as a common type of hypertrophic cardiomyop-
athy, is mainly characterized by asymmetric septal
hypertrophy, LVOT obstruction, diastolic dysfunction,
cardiac ischemia as well as arrhythmia [16–18]. The aim
of medical therapy is to abolish the catecholamine-
induced effects that may exacerbate LVOT obstruction
Table 3 Postoperative arrhythmia
Arrhythmia Number Percentage
Atrial fibrillation 24 17.3 %
Atrial premature beat 7 5.0 %
Ventricular premature beat 4 2.9 %
Atrioventricular block 16 11.5 %
Left bundle branch block 34 24.5 %
Left anterior fascicular block 10 7.2 %
Right bundle branch block 5 3.6 %
Fig. 1 Kaplan-Meier curve for HOCM patients during follow-up period. Survival rate and log survival rate decreased whereas cumulate hazard
gradually increased during follow-up time. The survival rate was 100 % at the first year after surgery and then decreased to 99.3 % at the second
and the third year. The survival rate was 98.5 % at the fourth year and reduced to 97.8 % at the fifth year
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and to decrease heart rate which allows longer time for
diastolic filling [17, 19, 20]. However, the early improve-
ment for HOCM patients is often followed by clinical
symptomatic impairments after conservative manage-
ment with beta-blocker and/or calcium antagonist [21].
With septal myectomy reduction therapy, the long-term
mortality for HOCM patients could significantly de-
crease to 1.4–1.8 % [7, 8].
Left ventricular septal myectomy was firstly reported by
Cleland in 1963 and Morrow subsequently revealed the
good clinical and hemodynamic outcomes of myectomy sur-
gery [22]. Isolated septal myectomy mainly resected the
bulge part of the hypertrophic septum. Some intraventricu-
lar anomalies such as mitral apparatus-related anomalies
existed in HOCM patients. Under the condition, isolated
septal myectomy could not diminish SAM of mitral valve
and relieve LVOT obstruction completely [10]. Marwick
et al. reported that up to 20 % of patients with isolated septal
myectomy were placed back on cardiopulmonary bypass be-
cause of inadequate resection [23]. An inadequate length of
septal excision was the most common reason of recurrent
LVOT obstruction after myectomy [24]. Extensive septal
myectomy to the midventricular level, with or without shav-
ing of the papillary muscles, could eliminate the LVOT gra-
dient and SAM-induced mitral regurgitation [25]. Knyshov
G et al. performed a cohort study in HOCM patients and
their results showed that LVOT gradient of HOCM patients
reduced from 113.3 ± 14.9 mmHg to 17.3 ± 10.2 mmHg
after extensive septal myectomy surgery [26].
Follow-up outcomes of extensive septal myectomy
surgery
Until now, there are limited data addressing long-term
outcomes of extensive septal myectomy in Chinese
HOCM patients. Wang et al. showed that extensive sep-
tal myectomy provided excellent relief from LVOT
Fig. 2 Improvement in cardiac function after extensive septal
myectomy. The numbers of patients in NYHA Class I-II and NYHA
Class III-IV were calculated before surgery, 2.5 years and 5 years after
surgery, respectively. χ2 test was performed to analyze the differences
among groups. There was significant difference in preoperative and
postoperative cardiac function (P< 0.05). There was no difference in
cardiac functions between 2.5 years after surgery and 5 years after
surgery (P> 0.05). n= 59 for NYHA Class I-II and n= 80 for NYHA Class
III-IV before surgery; n= 110 for NYHA Class I-II and n= 25 for NYHA Class
III-IV at 2.5 years after surgery; n= 117 for NYHA Class I-II and n= 15 for
NYHA Class III-IVat 5 years after surgery
Fig. 3 Changes in echocardiographic parameters during follow-up period. a. Changes in LVIDd during follow-up. b. Changes in IVS thickness
during follow-up. c. Changes in LVOTG during follow-up. There was significant decrease in LVOTG at 2.5 years and 5 years after surgery.
d. Changes in EF during follow-up. EF was elevated at 2.5 years and 5 years after extensive septal myectomy. LVIDd: diastole left ventricular inner
diameter; IVS: interventricular septal; LVOTG: left ventricular out tract gradient; EF: ejection fraction. *P < 0.05 vs preoperative group, #P < 0.05 vs
2.5 years group
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obstruction (91.8 ± 25.1 to 14.3 ± 13.4 mmHg, P < 0.05)
and satisfactory clinical outcomes for 93 HOCM patients
at early and mid-term follow-up [27]. Their study
showed that the 30-day and in-hospital mortality was
0 % [27]. After surgery, limiting symptoms were de-
creased while physical abilities were increased [27]. In
our study, the resection size was extended to release
adhesion of mitral papillary muscle with left ventricular
wall and satisfactory operative effects and clinical out-
comes were obtained. The symptoms of HOCM patients
undergoing extensive septal myectomy procedure in our
study were obviously mitigated after operation. Echocar-
diography results by our study showed LVOT gradient
and septal width of HOCM patients were significantly
reduced whereas their LVIDd, and EF were increased
after surgery. The most common postoperative compli-
cation was arrhythmia, which mainly consisted of left
bundle branch block, atrial fibrillation, atrioventricular
block and so on. In current study, the types and preva-
lence of perioperative arrhythmia were similar to the
previous reports [28–30].
Conclusion
Extensive septal myectomy and adjunctive procedures
provide excellent relief of symptoms and improve car-
diac function in Chinese HOCM patients with minimal
surgical risk. Further studies with larger number and
longer follow-up were expected to aim at examining the
clinical outcomes of extensive septal myectomy surgery.
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